ArticleCancer imaging : the official publication of the International Cancer Imaging Society2025
Effect of disappearing liver metastases during pre-ablation chemotherapy on the prognosis of percutaneous microwave ablation in synchronous colorectal liver metastases patients.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionDisappearing colorectal liver metastases (DLM) frequently occur during chemotherapy. However, DLM is not equivalent to pathologically complete response. This study aimed to investigate the effect of radiographic DLM on microwave ablation (MWA) in patients with synchronous colorectal liver metastases (CRLM).
methodsA retrospective review was performed for patients who accepted MWA following pre-ablation chemotherapy from January 2014 to December 2021. DLM was defined as undetectable tumors on pre-ablation contrast-enhanced imagings compared to the initial ones. Overall survival (OS) and intrahepatic progression-free survival (ihPFS) were analyzed and compared between patients with and without DLM. Univariate and multivariate cox regression were used to identify risk factors for OS and ihPFS. A propensity score matching (PSM) analysis was used to balance the patient demographics.
resultsSixty-eight patients with DLM and 97 without DLM were included. The 1-year, 3-year, and 5-year ihPFS rates were significantly lower for patients with DLM compared to those without DLM before and after PSM (55.7%, 36.8%, and 30.6% vs. 70.8%, 59.3%, and 52.0% before PSM, respectively, p = 0.012; 44.9%, 31.8%, and 21.2% vs. 72.3%, 58.8%, and 47.5% after PSM, respectively, p = 0.039). Twenty-three (33.8%) patients with DLM had DLM-site recurrences during follow-up. The OS was not statistically different between the two groups both before and after PSM (p-value = 0.11 and 0.49). Multivariable cox regression revealed DLM (HR = 2.2; 95% CI = 1.1-4.1; p-value = 0.009) was a risk factor for poor ihPFS.
conclusionPatients with DLM presented worse ihPFS, suggesting that to eradicate visible tumors before disappearance may be advantageous when synchronous CRLM is ablatable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.